In pilot studies we determined that pharmacodynamic confirmation of PARP inhibition would not be possible in GBM patients because poly(ADP-ribose) (the product of PARP activity) was essentially undetectable in untreated tumor specimens from 5 GBM patients that were obtained from a brain tumor biorepository (Supplementary Figure 4). Here, PARP1 is linked to neoplasm.